GLP-1 Drugs Transform More Than Waistlines as Usage Doubles

GLP-1 drugs are revolutionizing more than just waistlines, with nationwide usage doubling rapidly. These medications mimic the gut hormone glucagon-like peptide to signal fullness to the brain and slow gut motility. However, they often trigger GI side effects like nausea and vomiting, especially during dose changes.

How GLP-1 Drugs Work Beyond Weight Loss

GLP-1 drugs mimic a natural gut hormone called glucagon-like peptide (GLP). After meals, the stomach stretches and releases GLP, signaling the brain to stop eating.

"With GLP medications, they are the same molecules, stable over time," explained Khraishah. "So they kind of work on the brain to tell the brain, hey, you are full, but also work on the gut to slow down the gut motility."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Common Gastrointestinal Side Effects

These mechanisms can lead to GI intolerance, a major issue for patients. Symptoms include nausea, vomiting, and diarrhea.

"The most common side effects of those medications are gut-related symptoms, and that goes back to how those medications work," Khraishah said. These effects are most frequent when starting treatment or adjusting doses, stemming from delayed gastric emptying in the GI tract.

Source Information

Originally published by WKYC 3 Cleveland.Read the original article →

Keep exploring

Same topic: GLP-1

All GLP-1 articles →

Metabolic Health

New Obesity Pills in the UAE: Navigating Insurance Coverage for Wegovy and Foundayo

As new weight-loss medications enter the UAE market, patients are questioning insurance coverage. We break down the realities of policy, medical necessity, and the future of metabolic health.

2 min read

Healthcare Policy

Medicare Expands GLP-1 Coverage: What the 2027 Policy Shift Means for Seniors

The federal government has extended its commitment to fund GLP-1 obesity medications through 2027, shifting away from private insurer mandates to protect seniors from premium hikes.

2 min read

Medical Research

Tirzepatide vs. Semaglutide: A Comprehensive Guide to Cost and Health Outcomes

A new lifetime economic analysis suggests tirzepatide may offer superior long-term value and clinical outcomes compared to semaglutide for obesity management.

2 min read

More in GLP-1 Medications

Health & Wellness

Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat

The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.

7 min read

Health & Wellness

Alli Weight Loss Pill: FDA Flags Serious Kidney Risks

The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.

8 min read

Health & Wellness

Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure

GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.

8 min read